Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11. Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members. Results: A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%). Conclusions: This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.

A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease / Zhang, H., Targher, G., Byrne, C.D., Kim, S.U., Wong, V.W.-S., Valenti, L., Glickman, M., Ponce, J., Mantzoros, C.S., Crespo, J., Gronbaek, H., Yang, W., Eslam, M., Wong, R.J., Machado, M.V., Yu, M.-L., Ghanem, O.M., Okanoue, T., Liu, J.-F., Lee, Y.-H., et al.. - In: HEPATOLOGY INTERNATIONAL. - ISSN 1936-0533. - 18:4(2024), pp. 1178-1201. [10.1007/s12072-024-10702-5]

A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

Carubbi F.;
2024

Abstract

Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11. Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members. Results: A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%). Conclusions: This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.
2024
18
4
1178
1201
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease / Zhang, H., Targher, G., Byrne, C.D., Kim, S.U., Wong, V.W.-S., Valenti, L., Glickman, M., Ponce, J., Mantzoros, C.S., Crespo, J., Gronbaek, H., Yang, W., Eslam, M., Wong, R.J., Machado, M.V., Yu, M.-L., Ghanem, O.M., Okanoue, T., Liu, J.-F., Lee, Y.-H., et al.. - In: HEPATOLOGY INTERNATIONAL. - ISSN 1936-0533. - 18:4(2024), pp. 1178-1201. [10.1007/s12072-024-10702-5]
Zhang, H.; Targher, G.; Byrne, C. D.; Kim, S. U.; Wong, V. W. -S.; Valenti, L.; Glickman, M.; Ponce, J.; Mantzoros, C. S.; Crespo, J.; Gronbaek, H.; Y...espandi
File in questo prodotto:
File Dimensione Formato  
s12072-024-10702-5.pdf

Accesso riservato

Tipologia: VOR - Versione pubblicata dall'editore
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1367409
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 29
social impact